PREMARIN® INTRAVENOUS Adverse Reactions

(conjugated estrogens)

ADVERSE REACTIONS

See BOXED WARNINGS, WARNINGS, and PRECAUTIONS.

Premarin Intravenous for injection is indicated for short-term use. However, the warnings, precautions and adverse reactions associated with oral Premarin treatment should be taken into account.

The following adverse reactions have been identified during post-approval use of oral or intravenous Premarin. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Genitourinary system

 
Abnormal uterine bleeding/spotting.
 
Dysmenorrhea or pelvic pain.
 
Increase in size of uterine leiomyomata.
 
Vaginitis, including vaginal candidiasis.
 
Change in amount of cervical secretion.
 
Change in cervical ectropion.
 
Ovarian cancer.
 
Endometrial hyperplasia.
 
Endometrial cancer.

Breasts

 
Tenderness, enlargement, pain, discharge, galactorrhea.
 
Fibrocystic breast changes.
 
Breast cancer.

Cardiovascular

 
Deep and superficial venous thrombosis.
 
Pulmonary embolism.
 
Thrombophlebitis.
 
Myocardial infarction.
 
Stroke.
 
Increase in blood pressure.

Gastrointestinal

 
Nausea, vomiting.
 
Abdominal cramps, bloating.
 
Cholestatic jaundice.
 
Increased incidence of gallbladder disease.
 
Pancreatitis.
 
Enlargement of hepatic hemangiomas.
 
Ischemic colitis.

Skin

 
Chloasma or melasma that may persist when drug is discontinued.
 
Erythema multiforme.
 
Erythema nodosum.
 
Hemorrhagic eruption.
 
Loss of scalp hair.
 
Hirsutism.
 
Pruritis.
 
Rash.

Eyes

 
Retinal vascular thrombosis.
 
Intolerance to contact lenses.

Central Nervous System

 
Headache.
 
Migraine.
 
Dizziness.
 
Mental depression.
 
Exacerbation of chorea.
 
Nervousness.
 
Exacerbation of epilepsy.
 
Dementia.
 
Possible growth potentiation of benign meningioma.

Miscellaneous

 
Increase or decrease in weight.
 
Glucose intolerance.
 
Aggravation of porphyria.
 
Edema.
 
Arthralgia.
 
Leg cramps.
 
Changes in libido.
 
Urticaria.
 
Hypocalcemia (preexisting condition).
 
Injection site pain.
 
Injection site edema.
 
Phlebitis (injection site).
 
Exacerbation of asthma.
 
Increased triglycerides.

Find PREMARIN® INTRAVENOUS medical information:

Find PREMARIN® INTRAVENOUS medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PREMARIN® INTRAVENOUS Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Adverse Reactions

ADVERSE REACTIONS

See BOXED WARNINGS, WARNINGS, and PRECAUTIONS.

Premarin Intravenous for injection is indicated for short-term use. However, the warnings, precautions and adverse reactions associated with oral Premarin treatment should be taken into account.

The following adverse reactions have been identified during post-approval use of oral or intravenous Premarin. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Genitourinary system

 
Abnormal uterine bleeding/spotting.
 
Dysmenorrhea or pelvic pain.
 
Increase in size of uterine leiomyomata.
 
Vaginitis, including vaginal candidiasis.
 
Change in amount of cervical secretion.
 
Change in cervical ectropion.
 
Ovarian cancer.
 
Endometrial hyperplasia.
 
Endometrial cancer.

Breasts

 
Tenderness, enlargement, pain, discharge, galactorrhea.
 
Fibrocystic breast changes.
 
Breast cancer.

Cardiovascular

 
Deep and superficial venous thrombosis.
 
Pulmonary embolism.
 
Thrombophlebitis.
 
Myocardial infarction.
 
Stroke.
 
Increase in blood pressure.

Gastrointestinal

 
Nausea, vomiting.
 
Abdominal cramps, bloating.
 
Cholestatic jaundice.
 
Increased incidence of gallbladder disease.
 
Pancreatitis.
 
Enlargement of hepatic hemangiomas.
 
Ischemic colitis.

Skin

 
Chloasma or melasma that may persist when drug is discontinued.
 
Erythema multiforme.
 
Erythema nodosum.
 
Hemorrhagic eruption.
 
Loss of scalp hair.
 
Hirsutism.
 
Pruritis.
 
Rash.

Eyes

 
Retinal vascular thrombosis.
 
Intolerance to contact lenses.

Central Nervous System

 
Headache.
 
Migraine.
 
Dizziness.
 
Mental depression.
 
Exacerbation of chorea.
 
Nervousness.
 
Exacerbation of epilepsy.
 
Dementia.
 
Possible growth potentiation of benign meningioma.

Miscellaneous

 
Increase or decrease in weight.
 
Glucose intolerance.
 
Aggravation of porphyria.
 
Edema.
 
Arthralgia.
 
Leg cramps.
 
Changes in libido.
 
Urticaria.
 
Hypocalcemia (preexisting condition).
 
Injection site pain.
 
Injection site edema.
 
Phlebitis (injection site).
 
Exacerbation of asthma.
 
Increased triglycerides.
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.